[go: up one dir, main page]

DE69425890D1 - Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide - Google Patents

Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide

Info

Publication number
DE69425890D1
DE69425890D1 DE69425890T DE69425890T DE69425890D1 DE 69425890 D1 DE69425890 D1 DE 69425890D1 DE 69425890 T DE69425890 T DE 69425890T DE 69425890 T DE69425890 T DE 69425890T DE 69425890 D1 DE69425890 D1 DE 69425890D1
Authority
DE
Germany
Prior art keywords
antisense oligonucleotides
kaposi sarcoma
treating kaposi
treating
sarcoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69425890T
Other languages
English (en)
Inventor
Barbara Ensoli
C Gallo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Office of Technology Transfer
Original Assignee
US Department of Health and Human Services
Office of Technology Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Office of Technology Transfer filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69425890D1 publication Critical patent/DE69425890D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69425890T 1993-06-04 1994-05-17 Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide Expired - Lifetime DE69425890D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7257593A 1993-06-04 1993-06-04
PCT/US1994/005467 WO1994029444A1 (en) 1993-06-04 1994-05-17 Method for treating kaposi's sarcoma with antisense oligonucleotides

Publications (1)

Publication Number Publication Date
DE69425890D1 true DE69425890D1 (de) 2000-10-19

Family

ID=22108493

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69425890T Expired - Lifetime DE69425890D1 (de) 1993-06-04 1994-05-17 Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide

Country Status (8)

Country Link
US (1) US5990088A (de)
EP (1) EP0703979B1 (de)
JP (1) JPH10510700A (de)
AT (1) ATE196313T1 (de)
AU (1) AU693097B2 (de)
CA (1) CA2164288A1 (de)
DE (1) DE69425890D1 (de)
WO (1) WO1994029444A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
AU696393B2 (en) * 1995-06-07 1998-09-10 Gen-Probe Incorporated Use of antisense oligonucleotides to IL-6 receptor mRNA to inhibit cellular proliferation
US5716846A (en) * 1995-06-07 1998-02-10 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA
WO1998003646A1 (en) * 1996-07-22 1998-01-29 Hybridon, Inc. Compositions and methods for treating specific gene expression-related diseases and disorders in humans
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
PT1212422E (pt) 1999-08-24 2007-04-30 Medarex Inc Anticorpos contra citla-4 humana e suas utilizações
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2425779C (en) 2000-10-12 2013-08-06 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
MXPA04007586A (es) 2002-02-06 2005-06-08 Vicor Technologies Inc Moleculas anti-infarto.
CA2481207C (en) 2002-04-12 2015-06-30 Medarex, Inc. Methods of treatment using ctla-4 antibodies
WO2004013160A2 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
DK1613750T3 (en) 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
CA2564868C (en) * 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
EP3153525A1 (de) 2005-03-23 2017-04-12 Genmab A/S Antikörper gegen cd38 zur behandlung von multiplem myelom
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP2392646A1 (de) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1957115B8 (de) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Verfahren zur behandlung von ovarial- und nierenkarzinom mit antikörpern gegen t-zell-immunglobulin-domänen- und mucin-domänen-1-(tim-1)-antigen
US8110194B2 (en) 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
EP2010567A2 (de) 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antikörperzusammensetzungen und verfahren zur behandlung von neoplasien
EP3034083B1 (de) 2006-09-21 2020-12-09 University of Rochester Antisense-oligonukleotide zur behandlung von myotoner dystrophie
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
BRPI0720038A2 (pt) 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
EP2185719B1 (de) 2007-08-02 2013-11-13 NovImmune SA Rantes-antikörper und verfahren zu ihrer verwendung
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
CN102137680A (zh) * 2008-07-01 2011-07-27 克格诺西有限公司 用apoe肽治疗癌症的方法
CA2734322A1 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
BRPI1014544B8 (pt) 2009-05-05 2021-05-25 Novimmune Sa anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
US8442767B2 (en) * 2009-08-28 2013-05-14 Navteq B.V. Method of operating a navigation system to provide route guidance
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
CA2823191A1 (en) 2010-01-06 2011-07-14 Cognosci, Inc. Apoe peptide dimers and uses thereof
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US8435525B1 (en) * 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9249226B2 (en) 2010-06-09 2016-02-02 Genmab A/S Antibodies against human CD38
EP2633317A1 (de) 2010-10-25 2013-09-04 Genentech, Inc. Behandlung von magen-darm-entzündung und psoriasis a
WO2012099871A1 (en) 2011-01-17 2012-07-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of lrch4 activity and therapeutic application thereof
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
MX360772B (es) 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
US9970002B2 (en) 2012-12-12 2018-05-15 Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
KR102276974B1 (ko) 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
US10441637B2 (en) 2013-11-21 2019-10-15 Sena Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
MX2019001084A (es) 2016-07-28 2019-06-10 Regeneron Pharma Variantes de gpr156 y usos de estas.
EP3496736A4 (de) 2016-08-03 2020-05-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gegen tlr9 gerichtete therapeutika
BR112019014841A2 (pt) 2017-01-23 2020-04-28 Regeneron Pharma rna guia, uso do rna guia, rna antissentido, sirna ou shrna, uso do rna antissentido, do sirna ou do shrna, ácido nucleico isolado, vetor, composição, célula, e, métodos para modificar um gene hsd17b13 em uma célula, para diminuir a expressão de um gene hsd17b13 em uma célula, para modificar uma célula e para tratar um indivíduo que não é portador da variante de hsd17b13
EP3635102A1 (de) 2017-06-05 2020-04-15 Regeneron Pharmaceuticals, Inc. B4galt1-varianten und verwendungen davon
WO2019050899A1 (en) 2017-09-06 2019-03-14 Regeneron Pharmaceuticals, Inc. SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 (SIGIRR) RELATED INTERCEPTOR-RELATED VARIANTS AND USES THEREOF
CA3074682A1 (en) 2017-09-07 2019-03-14 Regeneron Pharmaceuticals, Inc. Solute carrier family 14 member 1 (slc14a1) variants and uses thereof
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
SG11202003254SA (en) 2017-10-11 2020-05-28 Regeneron Pharma Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
CA3079167A1 (en) 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. Cornulin (crnn) variants and uses thereof
WO2021003295A1 (en) 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
WO2024173343A1 (en) 2023-02-14 2024-08-22 Regeneron Pharmaceuticals, Inc. Compounds targeting hydroxysteroid 17-beta dehydrogenase (hsd17b) and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470824A (en) * 1991-05-31 1995-11-28 The Regents Of The University Of California Method to treat Kaposi's sarcoma
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
AU6951294A (en) 1995-01-03
JPH10510700A (ja) 1998-10-20
EP0703979A1 (de) 1996-04-03
US5990088A (en) 1999-11-23
CA2164288A1 (en) 1994-12-22
EP0703979B1 (de) 2000-09-13
WO1994029444A1 (en) 1994-12-22
ATE196313T1 (de) 2000-09-15
AU693097B2 (en) 1998-06-25

Similar Documents

Publication Publication Date Title
DE69425890D1 (de) Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DE69631613D1 (de) Mit Verriegelungsmechanismus versehene Vorrichtung zur chirurgischen Behandlung von Gewebe
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
DE69415100D1 (de) Vliesstoffgegenstand zur Behandlung von Oberflächen, Verfahren zur Herstellung und Verwendung davon
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
DE69008820D1 (de) Verfahren zur Behandlung von Polymerisaten.
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
DE19975051I2 (de) 5,11-Dihydro-6H-dipyrido(3,2-b:2'3'-e)(1,4)diazepine und ihre Verwendung zur Verhinderung oder Behandlung von HIV-Infektionen.
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE60022380D1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin-phosphorylase-hemmer zur behandlung von hiv
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE261737T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
EP0608212A4 (de) Verfahren zur behandlung viraler infektionen.
GR3034155T3 (en) Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer
DE69330172D1 (de) Zusammensetzung für die Behandlung von Fasern, damit behandelte Fasern, und Verfahren zur Behandlung von Fasern mit dieser Zusammensetzung
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE69838980D1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DE69014501D1 (de) Verfahren zur Behandlung von Titanlegierung und damit hergestelltes Stück.
GR3033698T3 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections.
ATE227998T1 (de) Verwendung von substituierten dextranen zur behandlung von schädigungen des nervensystems, und fraktionen mit erhöhtem heparansulfat-gehalt
DE3885090D1 (de) Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil.

Legal Events

Date Code Title Description
8332 No legal effect for de